Comparison of the effects of postbiotics and live-probiotics containing Lacticaseibacillus paracasei SD1 and Lacticaseibacillus rhamnosus SD11 in patients with previous colorectal cancer: A randomized controlled trial

Abstract

Evidence suggests that probiotics can be used as functional food to improve colorectal cancer (CRC) conditions. Postbiotics can provide the same benefits as the live form. The present study aimed to compare the effects of postbiotics and live probiotics containing Lacticaseibacillus paracasei SD1 and Lacticaseibacillus rhamnosus SD11 in patients with previous colorectal cancer. Results revealed that pro-inflammatory cytokines levels (IL-1β, TNF-α, IL-6, IL-8, and IL-17A) significantly reduced in patients who received postbiotics and live-strains compared to at the beginning of the study. Butyrate and anti-inflammatory cytokines levels significantly increased in patients who received the postbiotics and live-strains. Gut microbiota and butyrate producers increased while the pathogen Fusobacterium decreased among patients taking the postbiotics and live-strains. In conclusion, both forms of L. paracasei SD1 and L. rhamnosus SD11 could deliver benefits for improvement of CRC conditions, which further expanded the application of the postbiotics from this clinical trial.

Keywords

• Postbiotics
• Probiotics
• Lacticaseibacillus paracasei SD1
• Lacticaseibacillus rhamnosus SD11
• Colorectal cancer